文献速递神经免疫

稳定型多发性硬化患者停用一线疾病修饰治疗:DOT-MS随机临床试验

Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项多中心、评估者盲法、非劣效性随机临床试验在14家荷兰中心纳入89例长期稳定的多发性硬化患者,1:1随机分配继续或停用一线疾病修饰治疗。中位随访15.3个月后,因停用组炎症活动复发超过预设上限而提前终止;停用组45例中8例(17.8%)达到主要终点,继续组44例中0例达到,停用组复发多为影像学炎症,其中2例为临床复发。

要点

  • 长期稳定超过5年的多发性硬化患者停用一线疾病修饰治疗后,炎症活动可复发。
  • 停用组45例中8例(17.8%)达到主要终点,继续组44例中0例达到。
  • 该试验因停用组炎症活动复发超过预设上限而提前终止,中位随访15.3个月。

核心结论

  • 在长期稳定超过5年的多发性硬化患者中,停用一线疾病修饰治疗可导致炎症活动复发,停用组复发显著高于继续组,也高于既往仅纳入55岁及以上人群的DISCOMS试验。

研究设计与样本

  • 多中心、评估者盲法、非劣效性随机临床试验,于2020年7月1日至2023年3月20日在14家荷兰中心开展,数据分析于2023年7月至2024年1月进行。
  • 纳入标准为复发起病型多发性硬化、年龄18岁及以上、既往5年一线疾病修饰治疗下无复发且无显著磁共振成像活动。
  • 163例潜在合格者中,试验提前终止时共纳入89例,按1:1随机分配至继续组44例(49.4%)和停用组45例(50.6%)。
  • 中位(IQR)年龄54.0(49.0-59.0)岁,女性60例(67.4%);继续组2例失访。

主要发现

  • 中位(IQR)随访15.3(11.4-23.9)个月后,试验因炎症活动复发超过预设上限而提前终止。
  • 停用组45例中8例(17.8%)达到主要终点,继续组44例中0例达到主要终点,复发多为影像学炎症,其中2例为临床复发。
  • 达到疾病活动的中位(IQR)时间为12.0(6.0-12.0)个月。
  • 主要终点定义为复发和/或脑磁共振成像出现3个及以上新T2病灶或2个及以上强化病灶。

局限性

  • 试验在纳入89例时提前终止,研究队列相对较小。
  • 停用组炎症复发显著高于继续组,也高于既往仅纳入55岁及以上人群的DISCOMS试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy. OBJECTIVE: To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, rater-blinded, noninferiority randomized clinical trial was conducted between July 1, 2020, and March 20, 2023, at 14 Dutch centers. Data analysis was performed between July 2023 and January 2024. Key inclusion criteria were relapse-onset MS, aged 18 years or older, without relapses, and without substantial magnetic resonance imaging (MRI) activity in the previous 5 years under first-line DMT. Participants were randomized 1:1 to discontinue or continue first-line DMT. INTERVENTION: Discontinuation of first-line DMT. MAIN OUTCOME AND MEASURE: The primary outcome was significant inflammatory disease activity, defined as relapse and/or 3 or more new T2 lesions or 2 or more contrast-enhancing lesions on brain MRI. RESULTS: Of 163 potentially eligible participants, 89 participants were included in the trial at the moment of early termination. Forty-four participants (49.4%) were assigned to the continue group and 45 participants (50.6%) were assigned to the discontinue group. Median (IQR) age was 54.0 (49.0-59.0) years, and 60 participants (67.4%) were female. Two participants in the continue group were lost to follow-up. After a median (IQR) follow-up time of 15.3 (11.4-23.9) months, the trial was prematurely terminated because of inflammatory disease activity recurrence above the predefined limit. In total, 8 of 45 participants in the discontinue group (17.8%) vs 0 of 44 participants in the continue group reached the primary end point and had recurrent, mostly radiological inflammation. Two of these 8 participants had a clinical relapse. Median (IQR) time to disease activity was 12.0 (6.0-12.0) months. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, even in patients with long-term MS stable for over 5 years, first-line DMT discontinuation can lead to recurrence of inflammatory disease activity. Although this study cohort was relatively small, the recurrence of inflammation in the discontinue group was significantly higher than in the continue group and also higher than in the previously published DISCOMS trial, which only included individuals aged 55 years or older. This study provides additional data, especially in a younger population and including longitudinal biomarker measurements, for informed decision-making in cases when treatment discontinuation is considered. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04260711.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Coerver EME, Fung WH, de Beukelaar J, et al. Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 39652340. doi:10.1001/jamaneurol.2024.4164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。